MEG3 and cancer: A recent meta-analysis has verified that low expression of MEG3 is significantly associated with poor prognosis for patients with different types of cancer (Binabaj et al., 2018), although GEPIA database analysis showed that changes in MEG3 expression had no significant effect on the OS and DFS in both LGG and GBM.